To examine this in our cancer models, we compared the expression of RARα, RARβ, RARγ, RXRα, RXRβ and RXRγ in AB1-HA tumors, which are sensitive to combination tretinoin–CY therapy, and AE17, CT26 and WEHI164 tumors, which are resistant. This evidence concerns the gene RARA and cancer.